ATHE

Business Context and Reporting Period

Company: Prana Biotechnology Limited (Note: Metadata listed "Alterity Therapeutics Ltd" but the filing text identifies the registrant as Prana Biotechnology Limited).

Filing Type: Form 6-K (Report of Foreign Private Issuer).

Reporting Period: Year ended June 30, 2005.

Filing Date: September 23, 2005.

Business Overview: Prana is a biotechnology company focused on research into Alzheimer's disease and other age-related degenerative disorders. The company operates primarily in Australia with newly established subsidiaries in the US and UK. The lead drug candidate, PBT2, is in Phase I clinical trials for Alzheimer's disease. Development of the previous candidate, PBT1, was terminated due to manufacturing difficulties.

Key Financial Metrics

Debt and Liquidity: The company reported no long-term debt. Total liabilities were approximately $2.7 million, primarily consisting of payables and provisions. Liquidity is supported by cash assets of approximately $21.5 million.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by 152.98% to $25.0 million. This was primarily driven by a non-cash impairment charge of $10.39 million related to the write-down of the Initial Platform Technology (IP) intangible asset to nil following the termination of the PBT1 trial.
• Revenue Growth: Revenue increased by 14.30% to $2.65 million.
• Expense Increases: Research & Development expenses rose to $7.69 million (from $5.24 million), and Personnel expenses increased to $4.05 million (from $2.77 million). Foreign exchange losses also surged to $1.36 million (from $0.18 million).
• Asset Reduction: Total assets decreased by approximately $19.1 million, largely due to the $10.4 million impairment of intangible assets and a reduction in cash balances.
• Equity Raising: The company raised $4.75 million through the exercise of 9.5 million options during the year.

Guidance, Outlook, and Risks

• Drug Development Outlook: PBT2 Phase I trials were initiated in Q1 2005. The company is screening PBT2 for other disease targets and designing next-generation compounds for Alzheimer's and Parkinson's diseases. Immunotherapy research is on track.
• Management Changes: Dr. Jonas Alsenas stepped down as CEO and Director in June 2005. Mr. Geoffrey Kempler resumed the dual role of Executive Chairman and CEO. Mr. Peter Marks was appointed as a Non-Executive Director in July 2005.
• Accounting Standards Transition: The company is transitioning to Australian equivalents to International Financial Reporting Standards (A-IFRS). Proforma statements indicate that under A-IFRS, the 2005 net loss would have been approximately $16.8 million (compared to $25.0 million under current GAAP) due to the derecognition of certain intangible assets and share-based payment adjustments.
• Risks: Key risks include the success of clinical trials for PBT2, the ability to raise further capital, and the impact of foreign exchange fluctuations. The write-down of IP assets reflects the risk associated with the failure of the PBT1 program.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $21.5 million cash balance given the operating cash outflow of $11.4 million and the capital-intensive nature of clinical trials.
• PBT2 Clinical Progress: Confirm the status and results of the Phase I trials for PBT2, as this is the primary value driver.
• Capital Requirements: Assess the need for future equity raises to fund the development pipeline and operations through 2006 and beyond.
• Intangible Asset Valuation: Review the rationale for the full write-down of the Initial Platform Technology and the potential for future impairments.
• A-IFRS Impact: Monitor the final adoption of A-IFRS standards and their effect on future reported earnings and equity.